TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo July 7, 2020 Joseph A. Wiley Chief Executive Officer Amryt Pharma plc Dept 920a 196 High Road, Wood Green London, United Kingdom N22 8HH Re: Amryt Pharma plc Amendment No. 1 to Registration Statement on Form F-1 Filed July 6, 2020 File No. 333-239395 Dear Dr. Wiley: We have reviewed your amended registration statement and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments. Amendment No. 1 to Form F-1 filed on July 6, 2020 Exhibits 1. Please have counsel file an amended opinion that does not include the assumptions set forth in paragraphs 3.1.4, 3.1.5, 3.1.6, 3.1.7 and, with respect to the Issued Shares, 3.1.8. Refer to Staff Legal Bulletin No. 19, Section II.B.3.a. Joseph A. Wiley Amryt Pharma plc July 7, 2020 Page 2 You may contact Gary Newberry at 202-551-3761 or Kevin Kuhar at 202-551-3662 if you have questions regarding comments on the financial statements and related matters. Please contact Christine Westbrook at 202-551-5019 or Suzanne Hayes at 202-551-3675 with any other questions. Sincerely, FirstName LastNameJoseph A. Wiley Division of Corporation Finance Comapany NameAmryt Pharma plc Office of Life Sciences July 7, 2020 Page 2 cc: Boris Dolgonos, Esq. FirstName LastName